Britain and America have signed a significant bilateral deal that will maintain zero tariffs on British medicine exports entering the US market.
Key Provisions of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise spending on drugs through the public health system. This move ensures that duties on these key exports will stay at zero for a duration of three years.
This agreement comes after previous statements to significantly raise import taxes on branded drug imports, with potential rates floated up to 100%.
"This deal with the United Kingdom bolsters the global environment for cutting-edge drugs and establishes long-overdue fairness to transatlantic drug exports," a statement noted.
Commercial Impact
Pharmaceuticals are one of the UK's most significant export categories to the America, which is clearly the biggest destination for large companies like GSK and AstraZeneca.
Trade data show that in the 12 months leading up to September, the UK shipped medicines totaling billions to the US. This figure accounted for a significant portion of total UK exports in that span.
"This deal protects jobs, increases investment and sets the stage for the UK to emerge as a international leader for biotech and pharma," a minister commented.
Key NHS Changes
The pact includes several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to increase total public funding on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than 20%.
Industry Background
This agreement follows a long-running row between the pharmaceutical industry and the ministers over medicine costs and NHS adoption.
This friction were intensified by arguments that American patients were paying significantly more for the same drugs than consumers in the other developed nations.
Recently, several major manufacturing plans in the UK have been delayed or cancelled, while substantial expansions have been pledged toward US facilities.
One official acknowledged that the NHS needed to invest a greater share on drugs, noting that its spending on drugs had shrunk as a share of its resources over the last ten years.
